Open AccessP526: REAL‐WORLD COMPARISON OF DIFFERENT TREATMENT MODALITIES FOR FAVORABLE RISK ACUTE MYELOID LEUKEMIA: STANDARD DOSE ANTHRACYCLINE VS HIGH DOSE ANTHRACYCLINE VS ADDITION OF GEMTUZUMAB OZOGAMICIN
Author(s) -
Mort J.,
Brewer B.,
Mautner B.,
Dibenedetto S.,
Pierce E.,
Morse E.,
Wells L.,
Ghamsari F.,
Morris A.,
Clark S.,
Reid J.,
Patel I.,
Jackson C.,
Perciavalle M.,
Yelvington B.,
Miller R.,
Abernathy K.,
Wolfe H.,
Locke S.,
Zeidner J.,
Reed D.,
Duong V.,
Dholaria B.,
LeBlanc T.,
Keng M.,
Horton B.,
El Chaer F.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000844992.77306.44
Subject(s) - gemtuzumab ozogamicin , anthracycline , medicine , cytarabine , daunorubicin , idarubicin , induction chemotherapy , regimen , population , myeloid leukemia , oncology , surgery , chemotherapy , cancer , stem cell , breast cancer , cd34 , cd33 , biology , environmental health , genetics